Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression
New Phase II data show vast majority of patients experiencing no relapses or disability progression
New Phase II data show vast majority of patients experiencing no relapses or disability progression
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Subscribe To Our Newsletter & Stay Updated